Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers
Status:
Active, not recruiting
Trial end date:
2022-03-30
Target enrollment:
Participant gender:
Summary
Since December 2019, the emergence of a new coronavirus named SARS-Cov-2 in the city of Wuhan
in China has been responsible for a major epidemic of respiratory infections, including
severe pneumonia. Within weeks, COVID-19 became a pandemic.
In the absence of specific antiviral treatment, a special attention should be given to
prevention. Personal protection equipments may be insufficiently protective, including in
healthcare workers, a significant proportion of whom (around 4%) having been infected in the
outbreaks described in China and more recently in Italy. Infection in healthcare workers
could result from the contact with COVID-19 people in community or with infected colleagues
or patients.
As it will take at least a year before vaccines against SARS-CoV-2 becomes available,
chemoprophylaxis is an option that should be considered in this setting where prevention of
SARS-CoV-2 infection in Health Care Workers.
The COVIDAXIS trial evaluates a chemoprophylaxis of SARS-CoV-2 infection in Health Care
Workers. This trial is divided into two distinct studies that could start independently each
with its own randomization process: COVIDAXIS 1 will study Hydroxychloroquine (HCQ) versus
placebo; COVIDAXIS 2 will study Lopinavir/ritonavir (LPV/r) versus placebo.
Upon randomization healthcare workers (HCWs) involved in the management of suspected or
confirmed COVID-19 cases will be assigned to one of the following 2 treatment groups: